Brief: JCR Pharmaceuticals Enters License Agreement With Alexion For Proprietary Just-Aav Capsids
08/07/2025 19:02
July 8 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T: JCR PHARMACEUTICALS ENTERS LICENSE AGREEMENT WITH ALEXION FOR PROPRIETARY JUST-AAV CAPSIDS TO BE USED IN THE DEVELOPMENT OF GENOMIC MEDICINES JCR PHARMACEUTICALS CO LTD - TO RECEIVE UP TO USD 825 MILLION IN MILESTONES Source text: ID:nBwHJnCZa Further company coverage: 4552.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results